![](/wp-content/uploads/2023/05/Screenshot-2023-05-19-at-2.51.11-PM.png)
$599
FDA Clears Beta Bionics iLet ACE Pump and iLet Dosing Decision Software
FDA announced it has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software, which form the insulin-only iLet Bionic Pancreas. A press release from Beta Bionics has not yet been observed. Recall, in May 2022, Beta Bionics presented results from its pivotal iLet Bionic Pancreas trial (view CT.gov record) at ATTD 2023 and disclosed that data from the trial was included in the comprehensive submission packaged filed with FDA (previous FENIX insight). Below, FENIX provides initial thoughts on the iLet approval.